{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:07:22Z","timestamp":1786982842382,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,11,25]],"date-time":"2014-11-25T00:00:00Z","timestamp":1416873600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s40618-014-0212-4","type":"journal-article","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T09:52:01Z","timestamp":1417427521000},"page":"447-453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience"],"prefix":"10.1007","volume":"38","author":[{"given":"A.","family":"Arduc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gokay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Isik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Ozuguz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Akbaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Tutuncu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Berker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. K.","family":"Kucukler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Guler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,25]]},"reference":[{"key":"212_CR1","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1056\/NEJMcp025334","volume":"349","author":"JA Schlechte","year":"2003","unstructured":"Schlechte JA (2003) Clinical practice: prolactinoma. N Engl J Med 349:2035\u20132041","journal-title":"N Engl J Med"},{"key":"212_CR2","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1210\/jc.2006-1668","volume":"91","author":"AF Daly","year":"2006","unstructured":"Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91:4769\u20134775","journal-title":"J Clin Endocrinol Metab"},{"key":"212_CR3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","volume":"72","author":"A Fernandez","year":"2010","unstructured":"Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol Oxf 72:377\u2013382","journal-title":"Clin Endocrinol Oxf"},{"key":"212_CR4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","volume":"27","author":"MP Gillam","year":"2006","unstructured":"Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27:485\u2013534","journal-title":"Endocr Rev"},{"key":"212_CR5","doi-asserted-by":"crossref","first-page":"8092","DOI":"10.1016\/S0021-9258(19)70612-7","volume":"255","author":"RA Maurer","year":"1980","unstructured":"Maurer RA (1980) Dopaminergic inhibition of prolactin synthesis and prolactin messenger RNA accumulation in cultured pituitary cells. J Biol Chem 255:8092\u20138097","journal-title":"J Biol Chem"},{"key":"212_CR6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0889-8529(05)70061-X","volume":"28","author":"ME Molitch","year":"1999","unstructured":"Molitch ME (1999) Medical treatment of prolactinomas. Endocrinol Metab Clin N Am 28:143\u2013169","journal-title":"Endocrinol Metab Clin N Am"},{"key":"212_CR7","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1210\/jcem-69-3-500","volume":"69","author":"I Pellegrini","year":"1989","unstructured":"Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A (1989) Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 69:500\u2013509","journal-title":"J Clin Endocrinol Metab"},{"key":"212_CR8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/jcem.82.3.3822","volume":"82","author":"A Colao","year":"1997","unstructured":"Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G (1997) Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 82:876\u2013883","journal-title":"J Clin Endocrinol Metab"},{"key":"212_CR9","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","volume":"84","author":"J Verhelst","year":"1999","unstructured":"Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518\u20132522","journal-title":"J Clin Endocrinol Metab"},{"key":"212_CR10","first-page":"1105","volume":"44","author":"J Webster","year":"1999","unstructured":"Webster J (1999) Dopamine agonist therapy in hyperprolactinemia. J Reprod Med 44:1105\u20131110","journal-title":"J Reprod Med"},{"key":"212_CR11","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/00003088-200342070-00003","volume":"42","author":"P Dotto Del","year":"2003","unstructured":"Del Dotto P, Bonuccelli U (2003) Clinical pharmacokinetics of cabergoline. Clin Pharmacok 42:633\u2013645","journal-title":"Clin Pharmacok"},{"key":"212_CR12","first-page":"575","volume":"169","author":"O Serri","year":"2003","unstructured":"Serri O, Chik CL, Ur Ehud, Ezzat S (2003) Diagnosis and management of hyperprolactinemia. Can Med Ass J 169:575\u2013581","journal-title":"Can Med Ass J"},{"key":"212_CR13","first-page":"E2","volume":"16","author":"JK Liu","year":"2004","unstructured":"Liu JK, Coldwell WT (2004) Contemporary management of prolactinomas. Neurosurg Focus 16:E2","journal-title":"Neurosurg Focus"},{"key":"212_CR14","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhoea. Cabergoline comparative study group. N Engl J Med 331:904\u2013909","journal-title":"N Engl J Med"},{"key":"212_CR15","first-page":"753","volume":"24","author":"V Pascal- Vigneron","year":"1995","unstructured":"Pascal- Vigneron V, Weryha G, Bosc M, Lectere J (1995) Hyperprolactinemic amenorrhea: treatment with cabergoline vs bromocriptine. Results of a national multicenter randomized double blind study. Press Med 24:753\u2013757","journal-title":"Press Med"},{"key":"212_CR16","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2169\/internalmedicine.40.857","volume":"40","author":"T Sabuncu","year":"2001","unstructured":"Sabuncu T, Arikan E, Tasan E, Hatemi H (2001) Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Intern Med 40:857\u2013861","journal-title":"Intern Med"},{"key":"212_CR17","first-page":"33","volume":"13","author":"A Al-Huseynei","year":"2008","unstructured":"Al-Huseynei A, Mahmood IH, Al-Jubori ZS (2008) Comparison of the effects of cabergoline and bromocriptine in women with hyperprolactinemic amenorrhea. Middle East Fertile Soc J 13:33\u201388","journal-title":"Middle East Fertile Soc J"},{"key":"212_CR18","first-page":"489","volume":"126","author":"C Ferrari","year":"1992","unstructured":"Ferrari C, Paracchi A, Mattei AM, de Vincentiis S, D\u2019Alberton A, Crosignani P (1992) Cabergoline in the long term therapy of hyperprolactinemic disorders. Arch Endocrinol (Copenh) 126:489\u2013494","journal-title":"Arch Endocrinol (Copenh)"},{"key":"212_CR19","first-page":"2338","volume":"81","author":"BM Biller","year":"1996","unstructured":"Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, Schoenfelder JR, Klibanski A (1996) Treatment of prolactin secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Meta 81:2338\u20132343","journal-title":"J Clin Endocrinol Meta"},{"key":"212_CR20","first-page":"2247","volume":"85","author":"A Colao","year":"2000","unstructured":"Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in na\u00efve patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrin Metab 85:2247\u20132252","journal-title":"J Clin Endocrin Metab"},{"key":"212_CR21","first-page":"301","volume":"22","author":"M Tartagni","year":"1995","unstructured":"Tartagni M, Nicastri PL, Diaferia A, Di Ges\u00f9 I, Loizzi P (1995) Long term follow-up of women with amenorrhea-galactorrhea treated with bromocriptine. Clin Exp Obstet Gynecol 22:301\u2013306","journal-title":"Clin Exp Obstet Gynecol"},{"key":"212_CR22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0028-2243(91)90101-P","volume":"40","author":"PF Heijden Van der","year":"1991","unstructured":"Van der Heijden PF, de Wit W, Brownell J, Rolland R (1991) CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia. Eur J Obstet Gynecol Reprod Biol 40:111\u2013118","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"212_CR23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1479-828X.1989.tb01712.x","volume":"29","author":"SA Al-Suleiman","year":"1989","unstructured":"Al-Suleiman SA, Najashi S, Rahman J (1989) Outcome of treatment with bromocriptine in patients with hyperprolactinaemia. Aust NZ J Obstet Gynaecol 29:176\u2013179","journal-title":"Aust NZ J Obstet Gynaecol"},{"key":"212_CR24","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1210\/jcem-60-4-698","volume":"60","author":"ME Molitch","year":"1985","unstructured":"Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO (1985) Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60:698\u2013705","journal-title":"J Clin Endocrinol Metab"},{"key":"212_CR25","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1210\/jc.2003-030979","volume":"89","author":"A Colao","year":"2004","unstructured":"Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, Zarrilli S, Lombardi G (2004) Outcome of cabergoline treatment in men with prolactinoma: effects of a 24\u00a0months treatment on prolactin levels, tumor mass, recovery of pituitary function and semen analysis. J Clin Endocrinol Metab 89:1704\u20131711","journal-title":"J Clin Endocrinol Metab"},{"key":"212_CR26","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","volume":"86","author":"A Sarno Di","year":"2001","unstructured":"Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86:5256\u20135261","journal-title":"J Clin Endocrinol Metab"},{"key":"212_CR27","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3109\/09513591003632233","volume":"26","author":"M Bahceci","year":"2010","unstructured":"Bahceci M, Sismanoglu A, Ulug U (2010) Comparison of cabergoline and bromocriptine in patients with asymptomatic incidental hyperprolactinemia undergoing ICSI-ET. Gynecol Endocrinol 26:505\u2013508","journal-title":"Gynecol Endocrinol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-014-0212-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-014-0212-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-014-0212-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T12:01:29Z","timestamp":1650715289000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-014-0212-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,25]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["212"],"URL":"https:\/\/doi.org\/10.1007\/s40618-014-0212-4","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,25]]}}}